Table 5. Analysis of the risk factors of respiratory syncytial virus related readmission after discharge from the NICU.
| Parameters | RSV-related readmission | Univariate analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | P value | Adjusted OR | 95% CI | P value | ||
| All infants (n = 1,140) | |||||||
| GA (week) | |||||||
| 25 or less | 11/77 (14.3%) | Ref. | Ref. | ||||
| 26-27 | 7/124 (5.6%) | 0.36 | (0.13-0.97) | 0.044 | 0.35 | (0.09-1.34) | 0.125 |
| 28-29 | 17/203 (8.4%) | 0.55 | (0.24-1.23) | 0.145 | 0.30 | (0.07-1.23) | 0.094 |
| 30-31 | 28/289 (9.6%) | 0.64 | (0.30-1.36) | 0.248 | 0.26 | (0.06-1.25) | 0.094 |
| 32-33 | 33/447 (7.4%) | 0.48 | (0.23-0.99) | 0.048 | 0.11 | (0.02-0.53) | 0.006 |
| Birth weight (g) | |||||||
| < 750 | 5/56 (8.9%) | 1.01 | (0.39-2.66) | 0.978 | 0.44 | (0.08-2.36) | 0.338 |
| 750-999 | 12/133 (9.0%) | 0.60 | (0.30-1.20) | 0.150 | 0.67 | (0.26-1.72) | 0.403 |
| 1,000-1,249 | 10/183 (5.5%) | 1.08 | (0.62-1.88) | 0.787 | 1.03 | (0.53-2.00) | 0.939 |
| 1,250-1,499 | 19/201 (9.5%) | 1.03 | (0.53-1.98) | 0.941 | 0.71 | (0.21-2.46) | 0.589 |
| ≥ 1,500 | 50/567(8.8%) | Ref. | Ref. | ||||
| Elder siblings | |||||||
| 0 (none) | 33/633 (5.2%) | Ref. | Ref. | ||||
| ≥1 | 63/466 (13.5%) | 2.84 | (1.83-4.41) | < 0.001 | 2.68 | (1.68-4.28) | < 0.001 |
| BPD | |||||||
| No | 64/806 (7.9%) | Ref. | Ref. | ||||
| Yes | 32/326 (9.8%) | 1.26 | (0.81-1.97) | 0.306 | 2.95 | (1.44-6.04) | 0.003 |
| Palivizumab prophylaxis | |||||||
| Yes | 15/507 (3.0%) | 0.21 | 0.06 | ||||
| No | 81/633 (12.8%) | Ref. | (0.12-0.37) | < 0.001 | Ref. | (0.03-0.13) | < 0.001 |
| Infants with BPD (n = 326) | |||||||
| GA (week) | |||||||
| 25 or less | 11/72 (15.3%) | Ref. | Ref. | ||||
| 26-27 | 4/94 (4.2%) | 0.25 | (0.08-0.81) | 0.021 | 0.36 | (0.07-1.95) | 0.237 |
| 28-29 | 10/96 (10.4%) | 0.64 | (0.26-1.61) | 0.348 | 0.51 | (0.10-2.69) | 0.425 |
| 30-31 | 7/49 (14.3%) | 0.92 | (0.33-2.58) | 0.880 | 0.47 | (0.06-3.96) | 0.487 |
| 32-33 | 0/15 (0%) | - | - | - | - | - | - |
| Birth weight (g) | |||||||
| < 750 | 5/51 (9.8%) | 0.42 | (0.12-1.45) | 0.170 | 0.24 | (0.03-2.35) | 0.223 |
| 750-999 | 11/101 (10.9%) | 0.18 | (0.05-0.67) | 0.010 | 0.18 | (0.03-1.23) | 0.080 |
| 1,000-1,249 | 4/89 (4.5%) | 0.42 | (0.12-1.45) | 0.170 | 0.20 | (0.03-1.18) | 0.075 |
| 1,250-1,499 | 5/51 (9.8%) | 0.47 | (0.17-1.33) | 0.157 | 0.55 | (0.08-3.91) | 0.550 |
| ≥ 1,500 | 7/34 (20.6%) | Ref. | Ref. | ||||
| Elder siblings | |||||||
| 0 (none) | 10/181 (5.5%) | Ref. | Ref. | ||||
| ≥1 | 22/133 (16.5%) | 3.39 | (1.55-7.43) | 0.002 | 5.82 | (1.95-17.32) | 0.002 |
| Severity of BPD | |||||||
| Mild | 15/161 (9.9%) | Ref. | Ref. | ||||
| Moderate | 6/103 (5.8%) | 0.60 | (0.23-1.61) | 0.311 | 0.72 | (0.21-2.41) | 0.591 |
| Severe | 11/62 (17.7%) | 2.10 | (0.91-4.87) | 0.084 | 1.19 | (0.34-4.17) | 0.786 |
| Palivizumab prophylaxis | |||||||
| Yes | 9/270 (3.3%) | 0.05 | (0.02-0.12) | < 0.001 | 0.03 | (0.01-0.08) | < 0.001 |
| No | 23/56 (41.1%) | Ref. | Ref. | ||||
A logistic regression model was used for the multivariate analysis. OR, odds ratio; CI, confidence interval; RSV, respiratory syncytial virus; GA, gestational age; NICU, neonatal intensive care unit; BPD, bronchopulmonary dysplasia.